fingolimod hydrochloride has been researched along with Respiratory Distress Syndrome in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amor, S; Baker, D; Giovannoni, G; Kang, AS; Schmierer, K | 1 |
| Ghobrial, RM; Kloc, M | 1 |
| Bai, C; Chen, H; Huang, Z; Liu, G; Liu, H; Niu, W; Qin, Y; Wen, G; Zhang, X; Zhao, Y; Zhu, C | 1 |
| Burne, MJ; Garcia, JG; Hassoun, PM; McVerry, BJ; Pearse, D; Peng, X; Rabb, H; Sammani, S; Tuder, RM | 1 |
1 review(s) available for fingolimod hydrochloride and Respiratory Distress Syndrome
| Article | Year |
|---|---|
The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic.
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Viral; Betacoronavirus; CD8-Positive T-Lymphocytes; Cladribine; Coronavirus Infections; COVID-19; Crotonates; Cytokine Release Syndrome; Deprescriptions; Dimethyl Fumarate; Fingolimod Hydrochloride; Glatiramer Acetate; Hematopoietic Stem Cell Transplantation; Humans; Hydroxybutyrates; Immune Evasion; Immunity, Innate; Immunologic Factors; Immunosuppressive Agents; Interferon-beta; Lymphopenia; Macrophages; Monocytes; Multiple Sclerosis; Natalizumab; Nitriles; Pandemics; Pneumonia, Viral; Respiratory Distress Syndrome; SARS-CoV-2; Toluidines | 2020 |
3 other study(ies) available for fingolimod hydrochloride and Respiratory Distress Syndrome
| Article | Year |
|---|---|
The multiple sclerosis (MS) drugs as a potential treatment of ARDS in COVID-19 patients.
Topics: Azetidines; Benzyl Compounds; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Enzyme Inhibitors; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Pandemics; Pneumonia, Viral; Respiratory Distress Syndrome; rhoA GTP-Binding Protein; SARS-CoV-2 | 2020 |
Transcriptomic analysis of lung tissues after hUC-MSCs and FTY720 treatment of lipopolysaccharide-induced acute lung injury in mouse models.
Topics: Acute Lung Injury; Animals; Combined Modality Therapy; Female; Fingolimod Hydrochloride; Gene Expression Profiling; Immunosuppressive Agents; Lipopolysaccharides; Lung; Mesenchymal Stem Cell Transplantation; Mice, Inbred C57BL; Respiratory Distress Syndrome | 2018 |
Protective effects of sphingosine 1-phosphate in murine endotoxin-induced inflammatory lung injury.
Topics: Animals; Bronchoalveolar Lavage Fluid; Capillary Permeability; Disease Models, Animal; Endothelial Cells; Endotoxins; Fingolimod Hydrochloride; Immunosuppressive Agents; Kidney; Kidney Diseases; Lipopolysaccharides; Lung; Lysophospholipids; Male; Mice; Mice, Inbred C57BL; Neutrophils; Organ Size; Perfusion; Peroxidase; Pneumonia; Propylene Glycols; Respiratory Distress Syndrome; Sphingosine; Time Factors | 2004 |